Compare VVR & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVR | ASMB |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.9M | 512.1M |
| IPO Year | 1998 | 2010 |
| Metric | VVR | ASMB |
|---|---|---|
| Price | $2.94 | $29.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 659.4K | 321.1K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.91 | $20.23 |
| 52 Week High | $3.54 | $39.71 |
| Indicator | VVR | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 43.60 |
| Support Level | $2.95 | $25.86 |
| Resistance Level | $2.96 | $30.62 |
| Average True Range (ATR) | 0.02 | 1.74 |
| MACD | 0.00 | -0.55 |
| Stochastic Oscillator | 90.00 | 1.80 |
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective is to provide a high level of current income, consistent with preservation of capital. The Trust seeks to achieve its objectives by investing in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions. The Trust borrows money for investment purposes, which may create the opportunity for enhanced return, but also should be considered a speculative technique and may increase the Trust's volatility.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.